Focus on Lung Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 5
Volume 18
Issue 5

LUGANO, Switzerland-Women may be more vulnerable than men to the cancer-causing effects of smoking, according to a study presented at the 2009 European Multidisciplinary Conference in Thoracic Oncology.

LUGANO, Switzerland-Women may be more vulnerable than men to the cancer-causing effects of smoking, according to a study presented at the 2009 European Multidisciplinary Conference in Thoracic Oncology.

Swiss researchers studied 683 lung cancer patients who were referred to Kantonsspital St. Gallen between 2000 and 2005. The investigators found that women tended to be younger when they developed the cancer, despite having smoked, on average, significantly less than men.

“Our findings suggest that women may have an increased susceptibility to tobacco carcinogens,” reported Martin Frueh, MD, and colleagues.

Commenting on the study, Enriqueta Felip, MD, from Val d’Hebron University Hospital in Barcelona, noted that the results support a growing awareness that smoking presents greater risks to women than men.

Women tend to be more aware of other cancers, such as breast cancer, she said.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
Related Content